Piotr Alvarez says HILIC flips elution order for semaglutide and tirzepatide, helping catch impurities, while TFA faces likely PFAS limits.
Recap by typeshit. Full story at LCGC International.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Walmart is widening free prescriptions for staff while other big employers scale back drug benefits. The snippet doesn't say if GLP-1s are covered.
Post hoc ATTAIN data put weight loss at about 13% to 14% on the 36 mg dose whether women were pre, peri or postmenopausal. The results haven't been peer reviewed yet.
Loading…